FIELD: biotechnology; medicine.
SUBSTANCE: invention relates to a composition comprising double-stranded RNA (dsRNA) having two complementary strands comprising at least one poly(A) unit and a poly(U) complementary unit, wherein each chain has length of 50 to 200 bases, preferably from 55 to 200 bases, as well as a pharmaceutically acceptable solvent, carrier or excipient for use in a method of treating cancer expressing the TLR3 receptor.
EFFECT: invention provides dsRNA capable of both activating myeloid cells and triggering death of epithelial cancer cells.
19 cl, 20 dwg, 5 tbl, 20 ex
| Title | Year | Author | Number |
|---|---|---|---|
| INDUCTION OF APOPTOSIS IN TUMOUR CELLS, EXPRESSING TOLL-LIKE RECEPTOR | 2005 |
|
RU2401661C9 |
| VACCINE AGAINST Eimeria WITH IMPROVED EFFICIENCY | 2017 |
|
RU2764802C2 |
| CHAPERONIN 10 MODULATION OF TOLL-LIKE RECEPTOR INDUCIBLE CYTOKINE AND CHEMOKINE SECRETION | 2005 |
|
RU2446817C2 |
| SINGLE-CHAIN TRAIL-RECEPTOR AGONIST PROTEINS | 2015 |
|
RU2699285C2 |
| IMMUNOSTIMULATING G,U-CONTAINING OLYGORIBONUCLEOTIDES | 2003 |
|
RU2302865C2 |
| INDUCTION MEDIUM AND METHODS OF STEM CELL CULTIVATION AND THERAPY | 2015 |
|
RU2717983C2 |
| NUCLEIC ACIDS OF FORMULA (I) (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS IMMUNOSTIMULATING AGENTS/ADJUVANTS | 2009 |
|
RU2545701C2 |
| IMMUNOSTIMULATORY OLIGONUCLEOTIDES | 2012 |
|
RU2610690C2 |
| IMPROVED IMMUNOLOGICAL COMPOSITION | 2012 |
|
RU2664730C2 |
| IMMUNOSTIMULATING OLIGONUCLEOTIDES | 2009 |
|
RU2477753C2 |
